A study published on 31 August 2022 titled “Regular Use of Ivermectin as Prophylaxis for COVID-19 Led Up to a 92% Reduction in COVID-19 Mortality Rate in a Dose-Response Manner: Results of a Prospective Observational Study of a Strictly Controlled Population of 88,012 Subjects” by L. Kerr, F. Baldi, R. Lobo et al is another piece of evidence on the effectiveness of ivermectin.
There were 159,560 participants aged 18 years and above not infected with COVID-19 prior to July 7, 2020, from the city of Itajaí, Brazil. Among them, 45,716 (28.7%) did not use ivermectin and 113,844 (71.3%) used ivermectin prophylactically. Of the 113,844 participants, 8,325 (7.3%) subjects used ivermectin regularly and 33,971 (29.8%) used ivermectin irregularly. In total, 88,012 subjects were included in the present analysis. The 71,548 (62.8%) remaining participants used intermediate doses between 60 mg and 180 mg and were not included in this analysis.
The main body of the paper is approximately 36 pages long and worth a skim. Much of the page space is occupied by tables that present the breakdowns of each group.
The gist of it is that regular ivermectin users did better than irregular ivermectin users and, obviously, both groups did better than non-users. See Figure 4 and Figure 6 below.
Interestingly, the mortality rate of regular users is 84% lower than irregular users, and the mortality rate of irregular users is 37% lower than non-users. Also, the hospitalization rate of regular users is 98% lower than non-users, and the hospitalization rate of irregular users is 32% lower than non-users. This highlights the importance of regular use.
In other news, facemasks contain way too much titanium oxide for your own good. Wow, didn’t see that one coming.
Be sure to subscribe to our mailing list so you get each new Opinyun that comes out!
